by James Lyons-Weiler, PhD, Popular Rationalism, ©2025
(Apr. 7, 2025) — Finally, The Fork in the Road.. Never a More Exciting Time for Science, But WashPo is Debby Downer
On April 4, 2025, the Washington Post reported on the National Institutes of Health’s upcoming initiative to investigate the causes of autism spectrum disorder (ASD). Rather than welcoming this long-overdue development, the article fell back on narrative control, warning that revisiting vaccine-related hypotheses could damage public trust and fuel dangerous myths. It invoked the long-retracted 1998 Wakefield study as a talisman against scientific curiosity and reinforced a shallow binary: vaccines are either dangerous or they are not—and any scientific inquiry that fails to exonerate must be dangerous.
This framing fails not only the scientific method, but public health ethics. Real science begins with uncertainty, not decree. The NIH’s initiative must not be steered by ideology, political convenience, or institutional fear. It must be built on the foundation of rigorous, transparent, and predictive inquiry—not to confirm what is already believed, but to uncover what remains unknown.
The Silence That Spoke Volumes: A History of Institutional Abdication
For more than two decades, federal agencies, leading journals, and powerful professional organizations have refused to fund, publish, or even tolerate research that asks whether vaccine-related adverse events could play a role in autism onset. This wasn’t due to lack of plausible mechanisms. It was due to fear of liability, fear of reputational harm, and fear of undermining the narrative of universal vaccine safety.
This abdication of responsibility came in the wake of the 1986 National Childhood Vaccine Injury Act, which eliminated legal liability for vaccine manufacturers and transferred the burden of accountability to the public trust. Meanwhile, passive surveillance systems like VAERS—routinely criticized for underreporting—have remained the primary mechanism for tracking vaccine adverse events. Studies of vaccinated vs. unvaccinated populations have been systematically blocked. Attempts to reanalyze CDC data have led to whistleblower complaints, not transparency.
What has been lost is not just scientific knowledge but public trust. Without honest engagement, institutions hollow out their own credibility.
Science, Not Silence, Builds Trust
Public health authorities have spent years trying to persuade the public that any link between vaccines and autism is a myth. But they’ve largely relied on rhetorical tools, not data transparency. The suppression of inquiry, the vilification of parents, and the censorship of dissent have done far more to erode public confidence than any research study ever could.
Trust is not built by declaring questions off-limits. It is earned by facing uncertainty head-on. If NIH and HHS wish to restore public confidence, they must prove that they are willing to go where the evidence leads—even if the results are inconvenient. The American people do not need assurances. They need answers.
The World Is Watching: Aligning U.S. Research with Global Trends
Globally, the tide is already shifting. European and Asian researchers have begun to model vaccine responses in the context of genetic, immunological, and neurological variation. Studies in Japan have led to revised vaccine policies following adverse event signals. In France, aluminum adjuvant biopersistence has been explored as a potential neurotoxic contributor. Israel has begun tracking post-immunization inflammation using neural imaging technologies.
The United States is not leading this conversation. It is lagging. The NIH has the chance to reverse that, and to reclaim its place at the forefront of medical discovery—but only if it abandons its current defensive posture.
From Symptoms to Systems: A Call for Predictive, Preventive and Curative Research
Autism Spectrum Disorder is not a monolith. Its etiology is complex, multi-causal, and variable between individuals. Rather than asking again whether “vaccines cause autism,” NIH must shift toward a precision medicine model that asks: Which children, once vaccinated, are at highest risk of developing ASD? And can that risk be predicted before exposure?
To do this, NIH must fund prospective cohort studies that begin before vaccination and track biomarker profiles, family histories, mitochondrial efficiency, oxidative stress levels, and developmental baselines. These data must be analyzed using modern machine learning techniques that allow models to emerge from the data itself—empirical model selection—rather than assuming a predetermined statistical framework. Curve-fitting studies designed to exonerate based on null averages must give way to empirically validated, predictive models.
Importantly, these studies must track developmental deltas, not just static endpoints. Regression is not a checkbox—it is a trajectory. And it is precisely these changes over time that carry the deepest insights into risk.
Whole-Health Tracking and the Need for Longitudinal Design
The NIH must also redefine what constitutes a safety signal. Autism is not the only outcome of concern. Children must be tracked over years for neurological, immunological, metabolic, and psychiatric outcomes—across both vaccinated and unvaccinated groups, and across varying exposure timelines. The goal is not only to measure presence or absence of ASD, but to understand the broader health trajectories shaped by individual biology and environmental inputs.
This requires investment in systems-based longitudinal studies, integrated across disciplines. It means including glutathione support interventions, acetaminophen avoidance, dietary factors, and spacing of immunizations as experimental variables.
Read the rest here.
Years ago when there was a Charlie Rose program, he would periodically interview the leaders of the biomedical establishment. That would be the heads of the CDC, the FDA and the NIH. Calling in on this interview was one Andrew Grove, the former head of Intel who had suffered through, I think, prostate cancer. He was highly critical, based on his awful experiences, of the whole clinical system. Then he asked them a very interesting question, a question only an engineer would ask. If you took the whole system of clinical research, testing, and care apart, then put it back together again, would it be the same system? WOW, what an incredible question to ask.
Even more WOW was the response. Dead silence. They did not want to admit that the system would be very different if they went through that process. So he answered for them. Yes, it would be very different. That tells you everything you need to know about our biomedical establishment.